Dyadic Provides Alternative Proteins Business Update and Announces Attendance at Bioprocess International Conference [Yahoo! Finance]
Dyadic International, Inc. (DYAI)
NASDAQ:AMEX Investor Relations:
dyadic.com
Company Research
Source: Yahoo! Finance
At the conference, Dyadic will highlight its C1 and Dapibus™ microbial platforms, which are designed to improve the efficiency and lower the cost of manufacturing recombinant proteins such as: Recombinant human albumin: for use in cell culture media, diagnostics, and as a stabilizing agent for vaccine production. Bovine transferrin: for use in cell culture media and delivery of cancer therapeutics, among other uses. Human lactoferrin: for use in research and pharmaceutical applications as potential antimicrobial, anti-inflammatory, and immune-supportive products. Bovine alpha-lactalbumin: for use in products including infant formula, dietary supplements, and functional foods. As the Company enters the fourth quarter, Dyadic continues to advance partnerships supported by the Dapibus™ platform targeted at the alternative protein market, seeking near-term recurring revenue growth while continuing to advance the C1 platform in the animal and human health markets. Recent Devel
Show less
Read more
Impact Snapshot
Event Time:
DYAI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DYAI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DYAI alerts
High impacting Dyadic International, Inc. news events
Weekly update
A roundup of the hottest topics
DYAI
News
- Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology [Yahoo! Finance]Yahoo! Finance
- Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform TechnologyGlobeNewswire
- Dyadic International Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
- Dyadic International, Inc. (NASDAQ: DYAI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.MarketBeat
- Dyadic International Inc (DYAI) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic ... [Yahoo! Finance]Yahoo! Finance
DYAI
Earnings
- 11/12/24 - Beat
DYAI
Analyst Actions
- 11/14/24 - HC Wainwright
DYAI
Sec Filings
- 12/20/24 - Form 144
- 11/26/24 - Form 8-K
- 11/25/24 - Form 4
- DYAI's page on the SEC website